Xuewen Ma

449 total citations
15 papers, 230 citations indexed

About

Xuewen Ma is a scholar working on Hematology, Oncology and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, Xuewen Ma has authored 15 papers receiving a total of 230 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Hematology, 7 papers in Oncology and 7 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in Xuewen Ma's work include Multiple Myeloma Research and Treatments (12 papers), Monoclonal and Polyclonal Antibodies Research (7 papers) and CAR-T cell therapy research (4 papers). Xuewen Ma is often cited by papers focused on Multiple Myeloma Research and Treatments (12 papers), Monoclonal and Polyclonal Antibodies Research (7 papers) and CAR-T cell therapy research (4 papers). Xuewen Ma collaborates with scholars based in United States, Spain and Netherlands. Xuewen Ma's co-authors include Li Di, Edward H. Kerns, Guy T. Carter, Youping Huang, Brandi Hilder, Paula Rodríguez‐Otero, Niels W.C.J. van de Donk, María‐Victoria Mateos, Jaszianne Tolbert and Christoph Heuck and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Clinical Pharmacology & Therapeutics.

In The Last Decade

Xuewen Ma

11 papers receiving 221 citations

Peers

Countries citing papers authored by Xuewen Ma

Since Specialization

Citations

This map shows the geographic impact of Xuewen Ma's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Xuewen Ma with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Xuewen Ma more than expected).

Fields of papers citing papers by Xuewen Ma

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Xuewen Ma. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Xuewen Ma. The network helps show where Xuewen Ma may publish in the future.

Co-authorship network of co-authors of Xuewen Ma

This figure shows the co-authorship network connecting the top 25 collaborators of Xuewen Ma. A scholar is included among the top collaborators of Xuewen Ma based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Xuewen Ma. Xuewen Ma is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

15 of 15 papers shown

#	Work	Indexed citations
1	Recommended Phase II Doses of Talquetamab in Patients With Relapsed/Refractory Multiple Myeloma From MonumenTAL‐1: Clinical Pharmacology Results 2025 ·Clinical Pharmacology & Therapeutics ·(unknown), Jie Zhou, Dongfen Yuan, Xuewen Ma, Deeksha Vishwamitra, Brandi Hilder, Tara Masterson, Jaszianne Tolbert, Thomas Renaud, Christoph Heuck, Colleen Kane, Mahesh N. Samtani, Suzette Girgis, Nahor Haddish‐Berhane, Jesús G. Berdeja, (unknown), Danièle Ouellet	0
2	Evaluation of Drug–Drug Interaction Potential of Talquetamab, a T-Cell-Redirecting GPRC5D × CD3 Bispecific Antibody, as a Result of Cytokine Release Syndrome in Patients with Relapsed/Refractory Multiple Myeloma in MonumenTAL-1, Using a Physiologically Based Pharmacokinetic Model 2024 ·Targeted Oncology ·(unknown), (unknown), Brandi Hilder, Tara Masterson, Jaszianne Tolbert, Thomas Renaud, Christoph Heuck, Colleen Kane, Loeckie De Zwart, Suzette Girgis, Xuewen Ma, Danièle Ouellet	1
3	Results from a phase I/II trial of cusatuzumab combined with azacitidine in patients with newly diagnosed acute myeloid leukemia who are ineligible for intensive chemotherapy 2023 ·Haematologica ·Thomas Pabst, Norbert Vey, Lionel Adès, Ulrike Bacher, Mario Bargetzi, Samson Fung, Gianluca Gaïdano, Domenica Gandini, Anna Hultberg, Amy J. Wagoner Johnson, Xuewen Ma, Rouven Müller, Kerri Nottage, Cristina Papayannidis, Christian Récher, Carsten Riether, (unknown), (unknown), Liang Xiu, Adrian F. Ochsenbein	25
4	Efficacy, safety, pharmacokinetic (PK), and pharmacodynamic (PD) support for talquetamab (tal) QW and Q2W dosing in patients (pts) with relapsed/refractory multiple myeloma (RRMM): Analyses from MonumenTAL-1. 2023 ·Journal of Clinical Oncology ·Xuewen Ma, (unknown), Jie Zhou, Dongfen Yuan, Deeksha Vishwamitra, Brandi Hilder, Tara Masterson, Jaszianne Tolbert, Thomas Renaud, Christoph Heuck, Colleen Kane, Mahesh N. Samtani, Suzette Girgis, Jesús G. Berdeja, Amrita Krishnan, Danièle Ouellet	4
5	Analysis of infections and parameters of humoral immunity in patients (pts) with relapsed/refractory multiple myeloma (RRMM) treated with talquetamab (tal) monotherapy in MonumenTAL-1. 2023 ·Journal of Clinical Oncology ·Paula Rodríguez‐Otero, Carolina Schinke, Ajai Chari, Brea Lipe, Noa Lavi, Leo Rasche, Deeksha Vishwamitra, Sheri Skerget, Raluca Verona, Xuewen Ma, (unknown), Brandi Hilder, Tara Masterson, Michela Campagna, Thomas Renaud, Jaszianne Tolbert, Christoph Heuck, Marie-Anne Damiette Smit, Niels W.C.J. van de Donk	10
6	A Phase I, Randomized, Multi‐Dose Study to Evaluate the Enteric Selectivity and Safety of JAK Inhibitor, Lorpucitinib, in Healthy Participants 2023 ·Clinical Pharmacology & Therapeutics ·Xuewen Ma, Gary Borzillo, (unknown), (unknown), Gerald Chu, James Greger, Annemie Deiteren, Edward F. Attiyeh	0
7	POSTER: MM-191 Analysis of Infections and Parameters of Humoral Immunity in Patients (pts) With Relapsed/Refractory Multiple Myeloma (RRMM) Treated With Talquetamab (tal) Monotherapy in MonumenTAL-1 2023 ·Clinical Lymphoma Myeloma & Leukemia ·Paula Rodríguez‐Otero, Carolina Schinke, Ajai Chari, Brea Lipe, Noa Lavi, Leo Rasche, Deeksha Vishwamitra, Sheri Skerget, Raluca Verona, Xuewen Ma, (unknown), Brandi Hilder, Tara Masterson, Michela Campagna, Thomas Renaud, Jaszianne Tolbert, Christoph Heuck, (unknown), Niels W.C.J. van de Donk	0
8	P892: ANALYSIS OF INFECTIONS AND PARAMETERS OF HUMORAL IMMUNITY IN PATIENTS (PTS) WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM) TREATED WITH TALQUETAMAB (TAL) MONOTHERAPY IN MONUMENTAL-1 2023 ·HemaSphere ·Leo Rasche, Carolina Schinke, Ajai Chari, Brea Lipe, Noa Lavi, Paula Rodríguez‐Otero, Deeksha Vishwamitra, Sheri Skerget, Raluca Verona, Xuewen Ma, (unknown), Brandi Hilder, Tara Masterson, Michela Campagna, Thomas Renaud, Jaszianne Tolbert, Christoph Heuck, (unknown), Niels W.C.J. van de Donk	3
9	Pivotal phase 2 MonumenTAL-1 results of talquetamab (tal), a GPRC5DxCD3 bispecific antibody (BsAb), for relapsed/refractory multiple myeloma (RRMM). 2023 ·Journal of Clinical Oncology ·Carolina Schinke, Cyrille Touzeau, Monique C. Minnema, Niels W.C.J. van de Donk, Paula Rodríguez‐Otero, María‐Victoria Mateos, Leo Rasche, (unknown), Deeksha Vishwamitra, Xuewen Ma, Xiang Qin, Michela Campagna, Tara Masterson, Brandi Hilder, Jaszianne Tolbert, Thomas Renaud, Jenna D. Goldberg, Christoph Heuck, Ajai Chari	59
10	S191: PIVOTAL PHASE 2 MONUMENTAL-1 RESULTS OF TALQUETAMAB (TAL), A GPRC5DXCD3 BISPECIFIC ANTIBODY (BSAB), FOR RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM) 2023 ·HemaSphere ·Cyrille Touzeau, Carolina Schinke, Monique C. Minnema, Niels W.C.J. van de Donk, Paula Rodríguez‐Otero, María‐Victoria Mateos, Leo Rasche, (unknown), Deeksha Vishwamitra, Xuewen Ma, Xiang Qin, Michela Campagna, Tara Masterson, Brandi Hilder, Jaszianne Tolbert, Thomas Renaud, Jeffrey L. Goldberg, Christoph Heuck, Ajai Chari	15
11	Translational Modeling Predicts Efficacious Therapeutic Dosing Range of Teclistamab for Multiple Myeloma 2022 ·Targeted Oncology ·Suzette Girgis, Shun Xin Wang Lin, Kodandaram Pillarisetti, Arnob Banerjee, Tara Stephenson, Xuewen Ma, Shoba Shetty, Tong‐Yuan Yang, Brandi Hilder, Qun Jiao, (unknown), Homer Adams, Yu‐Nien Sun, Amarnath Sharma, Jennifer Smit, Jeffrey R. Infante, Jenna D. Goldberg, Yusri Elsayed	10
12	MonumenTAL-3: Phase 3 Trial of Talquetamab + Daratumumab ± Pomalidomide Versus Daratumumab + Pomalidomide + Dexamethasone in Relapsed/Refractory Multiple Myeloma Following ≥1 Prior Line of Therapy 2022 ·Blood ·Yaël C. Cohen, Philippe Moreau, Jaszianne Tolbert, Xiang Qin, Xuewen Ma, Diego Vieyra, (unknown), (unknown), W. Terry, Lixia Pei, Christoph Heuck, (unknown)	13
13	MonumenTAL-5: A Phase 3 Study of Talquetamab Versus Belantamab Mafodotin in Patients with Relapsed/Refractory Multiple Myeloma Who Received ≥4 Prior Lines of Therapy, Including a Proteasome Inhibitor, an Immunomodulatory Drug, and an Anti-CD38 Monoclonal Antibody 2022 ·Blood ·Shaji Kumar, Alfred L. Garfall, Suzanne Trudel, Enrique M. Ocio, Emma Scott, Lin Huang, Xuewen Ma, Yunsi Olyslager, Payal Thakkar, Lixia Pei, Christoph Heuck, Evangelos Terpos	1
14	Updated Phase 1 Results from MonumenTAL-1: First-in-Human Study of Talquetamab, a G Protein-Coupled Receptor Family C Group 5 Member D x CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Multiple Myeloma 2021 ·Blood ·Amrita Krishnan, Monique C. Minnema, Jesús G. Berdeja, Albert Oriol, Niels W.C.J. van de Donk, Paula Rodríguez‐Otero, Elham Askari, María‐Victoria Mateos, Luciano J. Costa, Raluca Verona, Xuewen Ma, Suzette Girgis, Shiyi Yang, Brandi Hilder, Jeffery S. Russell, Jenna D. Goldberg, Ajai Chari	40
15	Applications of High Throughput Microsomal Stability Assay in Drug Discovery 2008 ·Combinatorial Chemistry & High Throughput Screening ·Li Di, Edward H. Kerns, Xuewen Ma, Youping Huang, Guy T. Carter	49

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact